Figure 1.
Scheme of the study design. The flow chart represents a prospective, double-blind, randomized, single-center study with 149 participants. Participants were randomized into two groups: one receiving rosuvastatin alone (N=74), and the other receiving a combination of rosuvastatin and ezetimibe (N=75). Assessments were conducted at both baseline and after 12 weeks of medication for all participants. FACS, fluorescence activated cell sorting; PBMC, peripheral blood mononuclear cell.